Hormone replacement therapy and the changing conversation around safety

For many women navigating menopause, the question of whether hormone replacement therapy (HRT) is safe has lingered for years -sometimes in the background, sometimes with real anxiety. The facts haven’t always been clear, and for a long time, opinions were shaped more by fear than by careful interpretation of the science. Today, that narrative is shifting. What once felt like a risky option is being reconsidered through a more balanced and evidence-based lens, giving women a chance to revisit choices that were once dismissed. Thanks to a reversal of decades-long government policies that were based on shaky science, the picture is now much clearer, and HRT is back as a first-choice option that healthcare providers can consider.

The winds of change are blowing through Washington

On November 10, 2025, the U.S Department of Health and Human Services (HHS) acted to restore confidence in the use of HRT women’s health, after more than two decades of fear and misinformation surrounding hormone replacement therapy. The FDA is initiating the removal of broad “black box warnings” from HRT products that can be prescribed for  menopause.

Following a comprehensive review of the scientific literature, an expert panel in July, and a public comment period., the FDA accepted the recommendations to remove the “black-box warnings” that had raised doubts regarding the safety of HRT. Drug manufacturers can now change the language in their product labeling to remove references to risks of cardiovascular disease, breast cancer, and possible dementia. The warning of a risk of endometrial cancer for systemic estrogen-alone products remains.

Secretary of Health and Human Services Robert F. Kennedy Jr. encouraged women who have symptoms of menopause to start looking for valid options of approved and safe life-changing treatment. For more than twenty years, weak science and bureaucratic inertia resulted in women and physicians having a biased and unsustainable view of the risks vs. rewards of HRT. Now, with a return to evidence-based medicine, women are gaining control over their health again.

The FDA Commissioner (Marty Makary) also said that too many women have been denied the long-term benefits of hormone replacement therapy because of a medical dogma that was based on a distortion of the risk., meaning that issues of women’s health had been ignored. The decisions are for women and their physicians to take, based on data, not fear.

How hormone replacement therapy became controversial

The doubts about the safety of hormone replacement therapy can largely be traced back to a major study conducted in the early 2000s. Headlines at the time suggested links between HRT and serious conditions like breast cancer and heart disease. Understandably, both patients and doctors reacted quickly. Prescriptions dropped sharply, and many women were advised to stop treatment altogether.

But over time, a closer look revealed important limitations in that research. The average participant was older than the typical menopause patient, and the hormone formulations used were not the same as those commonly prescribed today. These details matter, and they significantly affect how the results could be interpreted.

A shift toward evidence-based understanding

Recent reviews of decades of data have led to a meaningful reassessment of hormone replacement therapy. Regulatory authorities in the United States have begun updating guidance, including the removal of broad black-box warning language that once emphasized risks such as cardiovascular disease, breast cancer, and dementia.

This change reflects a growing recognition that earlier interpretations overstated risks for many women, especially those starting treatment closer to the onset of menopause. For women under 60 or within 10 years of menopause, the balance of evidence suggests that benefits often outweigh potential risks when therapy is appropriately prescribed.

Menopause today: a longer chapter of life

Modern life expectancy has changed the context of menopause. Women are now spending a much larger portion of their lives in this stage, which makes symptom management and long-term health considerations more important than ever.

Estrogen plays a role far beyond reproduction. It supports cardiovascular function, bone health, cognitive processes, and even immune responses. When levels decline, the effects can ripple through multiple systems.

This broader understanding is part of what’s driving renewed interest in hormone replacement therapy, not as a quick fix, but as one option within a wider approach to managing menopause.

By restoring hormone levels, treatments like Estrogel Topical Gel, Mirena, Estring, Activella , AndroFeme cream, and Genotropin can help relieve symptoms and support long-term health in selected cases.

Why fear persisted for so long

It’s not unusual for medical narratives to lag behind evolving evidence. In the case of hormone replacement therapy, early messaging was strong and widely circulated. Once those ideas took hold, they proved difficult to reverse.

Many women avoided treatment altogether, even when symptoms significantly affected their quality of life. At the same time, some healthcare providers remained cautious, partly due to outdated perceptions of risk.

The result was a generation of women navigating menopause with fewer options than might have been available under a more balanced interpretation of the data.

Understanding what lower estrogen levels can do

At its core, hormone replacement therapy addresses the natural decline in estrogen and progesterone that occurs during menopause. These hormones play a central role in many body systems, which helps explain why their reduction can trigger a wide range of symptoms.

• Hot flashes and night sweats.
• Sleep disruption and fatigue.
• Mood changes and anxiety.
• Bone density loss.
• Vaginal dryness and discomfort.

By restoring hormone levels, common HRT treatments can help relieve symptoms and support long-term health.

What the research now suggests about safety

One of the most important updates in recent years is the recognition that timing matters. Women who begin hormone replacement therapy earlier – closer to the onset of menopause – appear to experience different outcomes than those who start much later.

Some studies have shown:

• Reduced risk of bone fractures and osteoporosis.
• Lower rates of cardiovascular disease in certain groups.
• Potential improvements in metabolic health.
• No clear increase in breast cancer risk with estrogen-only HRT.

These findings don’t mean that hormone replacement therapy is risk-free. Rather, they highlight the importance of individualized care. The decision to start therapy depends on personal health history, symptom severity, and ongoing medical guidance.

Comparison of common hormone replacement therapy options

Accessing treatments for menopause through IsraelPharm

Medications used in managing menopause, including options such as Estrogel Topical Gel and Estring, require a valid prescription and are selected based on individual clinical needs. IsraelPharm operates as an international licensed pharmacy supplier under the supervision of the Israeli Health Ministry, supporting access to prescribed treatments for menopause. For patients in USA, factors such as cost differences, insurance coverage gaps, or product availability may influence how and where medications are obtained, and IsraelPharm can provide an alternative pathway that offers cost savings, efficient delivery, product quality and safety..

Availability can vary depending on the specific medication, dosage, and delivery destination, and all treatment decisions must be guided by a qualified healthcare provider. Hormone replacement therapy is not a one-size-fits-all solution, and ongoing medical oversight is essential to ensure safety, effectiveness, and appropriate adjustments over time within the broader landscape of menopause care.

Frequently asked questions

Is hormone replacement therapy safe for most women?

Hormone replacement therapy is considered safe for many women, particularly those who begin treatment within 10 years of menopause or before age 60. The key factor is individualized assessment. A healthcare provider will evaluate personal risk factors such as cardiovascular history, cancer risk, and symptom severity. While earlier concerns focused heavily on potential risks, newer evidence suggests that for appropriately selected patients, the benefits – especially symptom relief and bone protection – can outweigh those risks. Regular monitoring is essential to maintain safety over time.

What is a black-box warning and why was it removed?

A black-box warning is the strongest safety warning issued on prescription medications. For hormone replacement therapy, these warnings were introduced based on early interpretations of large studies. However, more recent reviews found that those risks were overstated for many women, especially younger menopausal patients. As a result, regulators have begun removing broad warning language to better reflect current evidence. This does not mean HRT is risk-free, but it signals a more balanced understanding of its safety profile.

Does hormone replacement therapy increase cancer risk?

The relationship between hormone replacement therapy and cancer risk is complex. Estrogen-only HRT, typically used in women without a uterus, has not shown an increased risk of breast cancer in many studies. Combined estrogen-progesterone therapy may carry a slightly different risk profile, depending on duration and individual factors. Importantly, newer formulations and treatment approaches differ from those used in earlier studies. A personalized discussion with a healthcare provider is essential to understand individual risk.

Can hormone replacement therapy help with long-term health?

Beyond symptom relief, hormone replacement therapy may offer longer-term benefits for certain women. These include improved bone density, reduced fracture risk, and potential cardiovascular benefits when started early. Some research also suggests possible protective effects against metabolic conditions. However, these outcomes depend on timing, formulation, and patient characteristics. HRT should not be viewed as a universal preventive treatment, but rather as one option within a broader health strategy tailored to the individual.

Are there alternatives to hormone replacement therapy?

Yes, there are both hormonal and non-hormonal options available. Some women may use localized treatments, such as vaginal estrogen, for specific symptoms. Others may choose non-hormonal medications or lifestyle approaches to manage issues like hot flashes or sleep disturbances. Recently approved non-hormonal therapies offer additional choices for those who cannot or prefer not to use hormones. The best approach depends on symptom type, severity, and personal preferences, guided by medical advice.

When should someone consider starting hormone replacement therapy?

Timing plays a critical role in the effectiveness and safety of hormone replacement therapy. Many guidelines suggest considering HRT within 10 years of menopause onset or before age 60, when benefits are more likely to outweigh risks. Starting later may still be appropriate in some cases but requires more careful evaluation. Early consultation allows women to explore options before symptoms significantly impact daily life, making it easier to tailor treatment to their specific needs.

Glossary

Black-box warning: The strongest safety warning placed on prescription medications by regulatory authorities.

Estrogen: A primary female hormone involved in reproductive and overall body function.

Progesterone: A hormone that regulates menstrual cycles and balances estrogen effects.

Menopause: The stage when menstrual periods stop permanently, usually between ages 45 and 55.

Perimenopause: The transitional period before menopause when hormone levels begin to change.

Estrogen-only HRT: Hormone therapy using estrogen alone, typically for women without a uterus.

Osteoporosis: A condition where bones become weak and more likely to fracture.

Cardiovascular disease: Disorders affecting the heart and blood vessels.